Switzerland-based Novimmune, which counts Fracht as an investor, has now raised almost $230m and is working on cancer, inflammatory and autoimmune disease treatments.

Novimmune, a Switzerland-based biotechnology company backed by logistics services provider Fracht, has closed CHF30m ($29.8m) in funding from undisclosed existing investors.

The company is working on a range of antibody-based drugs to treat cancer, inflammatory diseases and immune-related disorders. Its lead product candidates are being developed to combat acute lymphocytic leukaemia and non-Hodgkin’s lymphoma.

The round took Novimmune’s total funding to about CHF230m, its last funding coming in a $66m round in 2014 led by life sciences-focused venture capital firm…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?